Fox Williams LLP acted for the London Technology Fund and Novartis Venture Fund, who were part of a consortium of investors which made a further investment of up to £8,650,000 into Immune Targeting Systems (ITS) Limited.
Immune Targeting Systems (ITS) Limited is developing a universal synthetic flu vaccine. The funding will progress ITS’s lead candidate through to the completion of phase-II proof of concept efficacy studies.
The London Technology Fund is a specialist investor in new technology companies and is focused on the funding gap for new, high growth technology companies based in Greater London.
Paul Osborne, Doug Preece and Sean Williams of Fox Williams LLP advised The London Technology Fund and Novartis Venture Fund.